Spruce Biosciences, INC Schedule 13G passive stakes

OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly filed a Schedule 13G, disclosing their beneficial ownership of Spruce Biosciences, Inc. common stock.

ADAR1 Capital Management and Daniel Schneeberger have updated their beneficial ownership filing for Spruce Biosciences, Inc., reporting a 2.5% stake as of June 30, 2026.

AWM Investment Company, Inc. has disclosed beneficial ownership of 146,988 shares, representing 5.1% of the outstanding common stock of Spruce Biosciences, Inc.

Integrated Core Strategies, Millennium Management, and Israel A. Englander report a reduction in their beneficial ownership of Spruce Biosciences, Inc. common stock to below 5%.

AIGH Capital Management and affiliated entities now beneficially own 9.1% of Spruce Biosciences' common stock, as disclosed in a Schedule 13G filing.

Alyeska Investment Group, L.P. and affiliates have reported a 4.49% beneficial ownership stake in Spruce Biosciences, Inc. as of March 31, 2026.

Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank have reported beneficial ownership of 12,200 shares, representing 0.9% of Spruce Biosciences, Inc. common stock.

Wellington Management Group LLP and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 3.6% of Spruce Biosciences, Inc. common stock as of March 31, 2026.

Ikarian Capital, LLC and Neil Shahrestani have filed an amendment to their Schedule 13G, reporting a 4.8% beneficial ownership stake in Spruce Biosciences Inc.

ExodusPoint Capital Management, LP, along with affiliated entities, has reported beneficial ownership of 0.8% of Spruce Biosciences, Inc. common stock as of April 27, 2026.

Millennium Management LLC and affiliated entities have disclosed a 9.6% passive beneficial ownership stake in Spruce Biosciences, Inc. common stock.

Squadron Master Fund LP and its affiliates have reported a 6.5% beneficial ownership stake in Spruce Biosciences, Inc., holding 70,000 shares of common stock.

Wellington Management Group LLP and its affiliates have reported a 5.5% beneficial ownership stake in Spruce Biosciences, Inc. common stock.

Peter David Boone has reported a 6.4% beneficial ownership stake in Spruce Biosciences, Inc., holding 68,184 shares of common stock.

Ikarian Capital, LLC and Neil Shahrestani have disclosed an 11.4% beneficial ownership stake in Spruce Biosciences Inc. common stock.

Citadel and its affiliates, including Kenneth Griffin, have reported a 9.99% beneficial ownership stake in Spruce Biosciences, Inc. through a Schedule 13G filing.

Squadron Master Fund LP and related entities have disclosed beneficial ownership of up to 6.6% of Spruce Biosciences, Inc. common stock.

Ikarian Capital, LLC and Neil Shahrestani have disclosed a 21.6% beneficial ownership stake in Spruce Biosciences Inc., holding 121,356 shares of common stock.

Rock Springs Capital and its affiliates have reported a complete divestment of their beneficial ownership in Spruce Biosciences, Inc.

The Radoff Family Foundation and Bradley L. Radoff have reported a complete divestment of their beneficial ownership in Spruce Biosciences, Inc. as of June 30, 2025.

Rosalind Advisors, Inc., Rosalind Master Fund L.P., and associated individuals Steven Salamon and Gil Aharon have reported a complete divestment of their beneficial ownership in Spruce Biosciences, Inc., now holding 0% of common shares.